SCHEMBL4797271

SCHEMBL4797271

NC(=O)N(Cc1ccccc1)c1cc[c]cc1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.50
ALDH1A1 P00352 1/20 0.50
GLA P06280 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
PAX8 Q06710 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TSPO P30536 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
PDK1 Q15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1385749 0.88 ALDH1A1 (0.62) NPC1ALDH1A1GLAHTTRAB9A
Hydrochloric Acid SCHEMBL27540694 0.86 NPC1 (0.61) NPC1ALDH1A1GLAHTTRAB9A
SCHEMBL8001968 0.83 TSPO (0.67) NPC1ALDH1A1GLAHTTRAB9A
SCHEMBL751298 0.83 NPC1 (0.46) NPC1ALDH1A1GLAHTTRAB9A
SCHEMBL8009229 0.82 NPC1 (0.57) NPC1ALDH1A1GLAHTTRAB9A
SCHEMBL8012651 0.82 NPC1 (0.62) NPC1ALDH1A1GLAHTTRAB9A
SCHEMBL3763981 0.81 LTB4R2 (0.56) NPC1ALDH1A1GLAHTTRAB9A
SCHEMBL27323388 0.80 NPC1 (0.50) NPC1ALDH1A1GLAHTTRAB9A
SCHEMBL5370995 0.78 ALOX5 (0.39) ALDH1A1GLAHTTSMN1; SMN2TSHR
SCHEMBL8016637 0.77 ALOX5 (0.57) NPC1ALDH1A1GLAHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107556267-A Novel thiazole derivates class compound, its preparation method, pharmaceutical composition and its pharmaceutical applications 中国人民解放军军事医学科学院毒物药物研究所 2018-01-09 CN disclosed
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1537112-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY Astrazeneca AB (SE) 2005-06-08 EP disclosed
WO-2004013141-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR NPC1 4851/4885ALDH1A1 2177/4885GLA 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.